170 related articles for article (PubMed ID: 15289083)
1. A conditionally replicating virus as a novel approach toward an HIV vaccine.
Das AT; Verhoef K; Berkhout B
Methods Enzymol; 2004; 388():359-79. PubMed ID: 15289083
[No Abstract] [Full Text] [Related]
2. Human immunodeficiency virus-1 tat- and tat/nef-defective genomes containing HIV-regulated diphtheria toxin A chain gene inhibit HIV replication.
Brdar B; Matulić M; Rubelj I; Ivanković M; Reich E
Croat Med J; 2002 Oct; 43(5):591-7. PubMed ID: 12402403
[TBL] [Abstract][Full Text] [Related]
3. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.
Devadas K; Boykins RA; Hewlett IK; Wood OL; Clouse KA; Yamada KM; Dhawan S
Peptides; 2007 Mar; 28(3):496-504. PubMed ID: 17188401
[TBL] [Abstract][Full Text] [Related]
4. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials.
Ensoli B; Fiorelli V; Ensoli F; Cafaro A; Titti F; Buttò S; Monini P; Magnani M; Caputo A; Garaci E
AIDS; 2006 Nov; 20(18):2245-61. PubMed ID: 17117011
[No Abstract] [Full Text] [Related]
5. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans.
Buttò S; Fiorelli V; Tripiciano A; Ruiz-Alvarez MJ; Scoglio A; Ensoli F; Ciccozzi M; Collacchi B; Sabbatucci M; Cafaro A; Guzmán CA; Borsetti A; Caputo A; Vardas E; Colvin M; Lukwiya M; Rezza G; Ensoli B;
J Infect Dis; 2003 Oct; 188(8):1171-80. PubMed ID: 14551888
[TBL] [Abstract][Full Text] [Related]
6. Tat toxoid: its potential role as an HIV vaccine.
Lambert J
J Hum Virol; 1998; 1(4):249-50. PubMed ID: 10195248
[No Abstract] [Full Text] [Related]
7. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
8. In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies.
Marzio G; Verhoef K; Vink M; Berkhout B
Proc Natl Acad Sci U S A; 2001 May; 98(11):6342-7. PubMed ID: 11353837
[TBL] [Abstract][Full Text] [Related]
9. Strict control of human immunodeficiency virus type 1 replication by a genetic switch: Tet for Tat.
Verhoef K; Marzio G; Hillen W; Bujard H; Berkhout B
J Virol; 2001 Jan; 75(2):979-87. PubMed ID: 11134311
[TBL] [Abstract][Full Text] [Related]
10. Construction of a doxycycline-dependent simian immunodeficiency virus reveals a nontranscriptional function of tat in viral replication.
Das AT; Klaver B; Harwig A; Vink M; Ooms M; Centlivre M; Berkhout B
J Virol; 2007 Oct; 81(20):11159-69. PubMed ID: 17670816
[TBL] [Abstract][Full Text] [Related]
11. Antibody to HIV-1 Tat protein, a key molecule in HIV-1 pathogenesis. A brief review.
Re MC; Gibellini D; Vitone F; La Placa M
New Microbiol; 2001 Apr; 24(2):197-205. PubMed ID: 11346305
[TBL] [Abstract][Full Text] [Related]
12. Construction of a selectable nef-defective live-attenuated human immunodeficiency virus expressing Escherichia coli gpt gene.
Tanuri A; Jesus da Costa L; Brindeiro R; Ramos CA; Pau CP; Rayfield MA
Virology; 2000 Mar; 268(1):79-86. PubMed ID: 10683329
[TBL] [Abstract][Full Text] [Related]
13. Modification of the Tet-On regulatory system prevents the conditional-live HIV-1 variant from losing doxycycline-control.
Zhou X; Vink M; Berkhout B; Das AT
Retrovirology; 2006 Nov; 3():82. PubMed ID: 17094796
[TBL] [Abstract][Full Text] [Related]
14. Conditional live virus as a novel approach towards a safe live attenuated HIV vaccine.
Das AT; Zhou X; Vink M; Klaver B; Berkhout B
Expert Rev Vaccines; 2002 Oct; 1(3):293-301. PubMed ID: 12901570
[TBL] [Abstract][Full Text] [Related]
15. The biochemistry of AIDS.
Vaishnav YN; Wong-Staal F
Annu Rev Biochem; 1991; 60():577-630. PubMed ID: 1883204
[No Abstract] [Full Text] [Related]
16. The TAR hairpin of human immunodeficiency virus type 1 can be deleted when not required for Tat-mediated activation of transcription.
Das AT; Harwig A; Vrolijk MM; Berkhout B
J Virol; 2007 Jul; 81(14):7742-8. PubMed ID: 17494072
[TBL] [Abstract][Full Text] [Related]
17. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.
Maggiorella MT; Baroncelli S; Michelini Z; Fanales-Belasio E; Moretti S; Sernicola L; Cara A; Negri DR; Buttò S; Fiorelli V; Tripiciano A; Scoglio A; Caputo A; Borsetti A; Ridolfi B; Bona R; ten Haaft P; Macchia I; Leone P; Pavone-Cossut MR; Nappi F; Ciccozzi M; Heeney J; Titti F; Cafaro A; Ensoli B
Vaccine; 2004 Sep; 22(25-26):3258-69. PubMed ID: 15308348
[TBL] [Abstract][Full Text] [Related]
18. Conditional virus replication as an approach to a safe live attenuated human immunodeficiency virus vaccine.
Berkhout B; Verhoef K; Marzio G; Klaver B; Vink M; Zhou X; Das AT
J Neurovirol; 2002 Dec; 8 Suppl 2():134-7. PubMed ID: 12491165
[TBL] [Abstract][Full Text] [Related]
19. Full-length HIV-1 Tat protein necessary for a vaccine.
Opi S; Péloponèse JM; Esquieu D; Watkins J; Campbell G; De Mareuil J; Jeang KT; Yirrell DL; Kaleebu P; Loret EP
Vaccine; 2004 Aug; 22(23-24):3105-11. PubMed ID: 15297062
[TBL] [Abstract][Full Text] [Related]
20. Attenuated HIV vaccine: caveats.
Ruprecht RM; Baba TW; Liska V
Science; 1996 Mar; 271(5257):1790-2. PubMed ID: 8596941
[No Abstract] [Full Text] [Related]
[Next] [New Search]
